Skip to main content

Table 2 Acute and late genitourinary and gastrointestinal toxicity

From: Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy

GU Toxicity

CTCAE highest gradea

During/End of RT (N = 69)

n (%)

End of Follow-up (N = 69)b

n (%)

 Dysuria

0

60 (87.0%)

65 (94.2%)

1

6 (8.7%)

3 (4.3%)

2

3 (4.3%)

0 (0.0%)

 Hematuria

0

69 (100.0%)

66 (95.7%)

1

0 (0.0%)

2 (2.9%)

 Urinary frequency

0

59 (85.5%)

59 (85.5%)

1

6 (8.7%)

8 (11.6%)

2

4 (5.8%)

1 (1.4%)

 Urinary incontinence

0

68 (98.6%)

57 (82.6%)

1

1 (1.4%)

10 (14.5%)

2

0 (0.0%)

1 (1.4%)

 Urinary retention

0

67 (97.1%)

57 (82.6%)

1

2 (2.9%)

11 (15.9%)

 Urinary urgency

0

57 (82.6%)

61 (88.4%)

1

12 (17.4%)

7 (10.1%)

 Highest grade of GU symptoms

0

44 (63.8%)

34 (49.3%)

1

18 (26.1%)

32 (46.6%)

2

7 (10.1%)

2 (2.9%)

3

0 (0.0%)

0 (0.0%)

GI Toxicity

CTCAE highest gradea

During/End of RT (N=69)

n (%)

End of Follow-up (N=69)

n (%)

 Anal or rectal hemorrhage

0

67 (97.1%)

68 (98.6%)

1

2 (2.9%)

1 (1.4%)

 Diarrhea

0

45 (65.2%)

67 (97.1%)

1

20 (29.0%)

2 (2.9%)

2

4 (5.8%)

0 (0.0%)

 Rectal pain

0

65 (94.2%)

69 (100%)

1

4 (5.8%)

0 (0.0%)

 Highest grade of GI symptoms

0

45 (65.2%)

66 (95.7%)

1

20 (29.0%)

3 (4.3%)

2

4 (5.8%)

0 (0.0%)

3

0 (0.0%)

0 (0.0%)

  1. Abbreviations: GU genitourinary, GI gastrointestinal, CTCAE Common Terminology Criteria of Adverse Events, RT radiation therapy
  2. atoxicity events were defined as symptoms increasing in grade over the respective baseline symptoms
  3. bone patient with no End of Follow up GU toxicity due to bladder resection in bladder cancer
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us